Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Trial With Combination Chemotherapy Consisting of Pegylated Liposomal Doxorubicin (PLD) and Carboplatin in Malignant Gynecologic Tumour's

NCT00189410 is registered in ClinicalTrials.gov with AGO Study Group as lead sponsor.

NCT NCT00189410
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00189410 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Trial With Combination Chemotherapy Consisting of Pegylated Liposomal Doxorubicin (PLD) and Carboplatin in Malignant Gynecologic Tumour's
Lead sponsor
AGO Study Group
Phase
Phase 2
Overall status
Completed
Start date
June 30, 2003
Completion date
September 30, 2006
Enrollment
140 (actual)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

cancer of the ovary treated as 2nd line therapy, cervical cancers, muellerian mixed tumours, non-epithelial ovarian tumours, tumours of the uterus